Cytokines: From the laboratory to the clinic

Drug Development Research

Volumn 46, Issue 3-4, 1999, Pages 197-205

  Nash, Andrew ^a,c   Kurek, John ^a   Hilton, Douglas ^b,c  

^a Zenyth Therapeutics Limited Australia   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Department of Civil and Environmental Engineering   (Australia)

Author keywords

Angiogenesis; Leukaemia inhibitory factor (LIF); Neuropathy; Suppressor of cytokine signaling (SOCS); Vascular endothelial growth factor (VEGF)

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; THROMBOPOIETIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; DEGENERATIVE DISEASE; DRUG RESEARCH; HUMAN; IMMUNOTHERAPY; MOTOR NEURON DISEASE; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROPATHY; NONHUMAN; TREATMENT INDICATION;

EID: 0032995988     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199903/04)46:3/4<197::AID-DDR5>3.0.CO;2-Z     Document Type: Article

References (56)

1. Achen M, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks A, Alitalo K, Stacker S. 1998. Vascular endothelail growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flkl) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548-533.
2. Adams TE, Hansen JA, Starr R, Nicola N, Hilton DJ, Billestrup N. 1998. Growth hormone preferentially induces the expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem 273:1285-1287.
3. Banner LR, Patterson PH, Allchorne A, Poole S, Woolf CJ. 1998. Leukemia inhibitory factor is an anti-inflammatory and analgesic cytokine. Neuroscience 18:5456-5462.
4. Bauman H, Symes AJ, Comeau MR, Morella KK, Wang Y, Corpus L, Friend D, Ziegler SR Fink JS, Gearing DP 1994. Multiple regions within the cytoplasmic domains of the leukaemia inhibitory factor and gp130 cooperate in signal transduction in hepatic and neuronal cells. Mol Cell Biol 14:138-146.
5. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. 1998. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123.
6. Bjørbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. 1998. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1:619-625.
7. Bower JJ, White JD, Kurek JB, Muldoon CM, Austin L. 1997. The role of growth factors in myoblast transfer therapy. Basic Appl Myol 7:177-189,
8. Campbell AM, Monge JC, Latter MA, Kuliszewski MA, Stewart DJ. 1998. Direct injection of vascular endothelial growth factor induces angiogenesis in non-ischaemic myocardium. J Am Coll Card 31:25A.
9. Cao Y, Chen H, Zhou L, Chiang M, Anand-Apte A, Weatherbee J, Wang Y, Fang F, Flanagan J, Tsang M. 1996. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271:3154-3162.
10. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpel K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
11. Cheema SS, Richards LR, Murphy M, Bartlett PF. 1994a. Leukemia inhibitory factor rescues motorneurones from axotomy-induced cell death. Neuroreport 5:989-992.
12. Cheema SS, Richards L, Murphy M, Bartlett PF. 1994b. Leukemia inhibitory factor prevents the death of axotomised sensory neurones in the dorsal root ganglion of the neonatal rat. J Neurosci Res 37:213-218.
13. Dey BR, Spence SL, Nissley P, Furlanetto RW. 1998. Interaction of the human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-1 receptor. J Biol Chem 273:24095-24101.
14. Donato R, Cheema S, Finkelstein D, Bartlett P, Morrison W. 1995. The role of leukaemia inhibitory factor (LIF) in rat peripheral nerve regeneration. Ann Acad Med Singapore 4:94-100.
15. Dowsing BJ, Morrison WA, Nicola NA, Starkey GP, Bucci GP, Kilpatrick TJ. 1998. LIF is an autocrine survival factor for Schwann cells (submitted for publication).
16. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura, A. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-924.
17. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K. 1997. Comparison of VEGF VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncogenes and hypoxia. Oncogene 14:2475-2483.
18. Ferrara N, Houck K, Jakeman L, Winer J, Leung D. 1991. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47:211-218.
19. Finkelstein D, Bartlett PF Home MK, Cheema SS. 1996. Leukaemia inhibitory factor is a myotrophic and neurotrophic agent that enhances the reinnervation of muscle in the rat. J Neurosci Res 46:122-128.
20. Folkmann J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
21. Folkmann J, Shing Y. 1992. Angiogenesis. J Biol Chem 267:10931-10934.
22. Fong G, Rossant J, Gertsenstein M, Breitman M. 1995. Role of the Flt-1 tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
23. Grimmond S, Lagercrantz J, Drinkwater C, Silins G, Townson S, Pollock P, Gotley D, Carson E, Rakar S, Nordenskjold M, Ward L, Hayward N, Weber G. 1996. Cloning and characterisation of a novel human gene related to vascular endothelial growth factor. Genome Res 6:124-131.
24. Hanahan D. 1997. Signaling vascular morphogenesis and maintenance. Science 277:48-50.
25. Hilton DJ. 1992. LIF: lots of interesting functions. Trends Biochem Sci 17:72-76.
26. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Wilson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf, D, Nicola NA. 1998. Twenty proteins containing a C-terminal SOCS box form five distinct structural classes. Proc Natl Acad Sci USA 95:114-119.
27. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. 1998. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95:9346-9354.
28. Houck K, Leung D, Rowland A, Winer J, Ferrara N. 1992. Dual regulation of vascular endothelial growth factor hioavailahility by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
29. Ikeda K, Iwasaki Y, Shiojima T, Kinoshita M. 1995. Neuroprotective effect of cholinergic differentiation leukaemia inhibitory factor on wobbler murine motor neurone disease. Muscle Nerve 18:1344-1347.
30. Ikeda K, Iwasaki Y, Shiojima T, Kinoshita M. 1996. Neuroprotective effect of various cytokines on developing spinal motorneurones following axotomy. J Neurol Sci 135:109-113.
31. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JE 1996. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348:370-374.
32. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain R, Alitalo K. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425.
33. Joukov V Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EM BO J 15:290-298.
34. Kurek JB, Bower JJ, White JD, Muldoon CM, Austin, L. 1998a. Leukaemia inhibitory factor and other cytokines as factors influencing regeneration of skeletal muscle. Basic Appl Myol (in press).
35. Kurek JB, Radford AJ, Crump DE, Bower JJ, Feeney SJ, Austin L, Byrne E. 1998b. LIF (AM424), a promising growth factor for the treatment of ALS. J Neurol Sci 160:5106-5113.
36. Lee J, Feldman A. 1998. Gene therapy for therapeutic myocardial angiogenesis: a promising synthesis of two emerging technologies. Nat Med 4:739-742.
37. Maglione D, Guerriero Y, Viglietto G, Ferraro M, Aprelikova O, Alitalo K, Vecchio S, Lei K, Chon J, Persico M. 1991. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271.
38. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STATS activation. Blood 89:3148-3154.
39. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924-929.
40. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson R, Alitalo K, Eriksson U. 1996a. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576-2581.
41. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, Eriksson U. 1996b. Genomic organisation of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterisation of second splice isoform. J Biol Chem 271: 19310-19317.
42. Sato T, Tozawa Y, Deutsch U, Wolburg-Bucholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. 1995. Distinct roles for the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-73.
43. Schindler C, Darnell JE. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64:621-651.
44. Schumacher B, Pecher P, von Specht BU, Stegmann T. 1998. Induction of neoangiogenesis in ischaemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97:645-650.
45. Shalaby F, Rossant J, Yamaguchi T, Gertsenstein M, Wu X, Breitman M, Schuh A. 1995. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66.
46. Stahl N, Boulton TG, Farrugella T, Ip NY, Davis S, Witthuhn A, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 P receptor components. Science 263:92-94.
47. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. 1997. A family of cytokine-inducible inhibitors of signaling. Nature 387:917-921.
48. Starr R, Metcalf D, Elefanty AC, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA (in press).
49. Taga T. 1996. Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem 67:1-10.
50. Takashita S, Zheng L, Brogi E, Kearny M, Pu L, Bunting S, Ferrara N, Symes J, Isner J. 1994. Therapeutic angiogenesis: a single intaarterial bolus of vascular endothelial growth factor augments revascularisation in a rabbit ischaemic hind limb model. J Clin Invest 93:662-670.
51. Tham S, Dowsing B, Finkelstein D, Donato R, Cheema SS, Bartlett PF, Morrison W. 1997. Leukaemia inhibitory factor enhances the regeneration of transected rat sciatic nerve and the function of reinnervated muscle. J Neurosci Res 47:208-215.
52. Thompson SW, Majithia AA. 1998. Leukemia inhibitory factor induces sympathetic sprouting in intact dorsal root ganglia in the adult rat in vivo. J Physiol 506:809-816.
53. Tian SS, Lamb P, King AG, Miller SG, Kessler L, Luengo JI, Averill L, Johnson RK, Gleason JG, Pelus LM, Dillon SB, Rosen J. 1998. A small, nonpeptidyl mimic of granulocyte-colony stimulating factor. Science 281:257-259.
54. Waring PM. 1997. Leukaemia inhibitory factor. In: Garland J, Queensberry P, Hilton D, editors. Colony stimulating factors: molecular and cellular biology. New York: Marcel Dekker. p 467-513.
55. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu JS, Isner JM. 1998. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 153:381-394.
56. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. 1995. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine phosphorylated interleukin-3 and erythropoietin receptors. EMBO J 14:2816-2826.